HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target
Iovance Biotherapeutics Inc +3.37% Pre
Iovance Biotherapeutics Inc IOVA | 11.03 11.05 | +3.37% +0.18% Pre |
HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:
IOVA) with a Buy and maintains $32 price target.